Comorbidities, N (%)b
| | | | | | |
Gastroesophageal reflux disease
|
82 (32.8 %)
|
26 (26.5 %)
|
45 (31.7 %)
|
0.999
|
0.999
|
0.999
|
Cardiac disorder
|
43 (17.2 %)
|
28 (28.6 %)
|
34 (23.9 %)
|
0.260
|
0.999
|
0.053
|
Metabolic disorder
|
38 (15.2 %)
|
20 (20.4 %)
|
29 (20.4 %)
|
0.500
|
0.999
|
0.642
|
Other vascular disorder
|
32 (12.8 %)
|
23 (23.5 %)
|
27 (19.0 %)
|
0.300
|
0.999
|
0.069
|
Pulmonary hypertension
|
31 (12.4 %)
|
20 (20.4 %)
|
16 (11.3 %)
|
0.999
|
0.095
|
0.198
|
Emphysema
|
18 (7.2 %)
|
8 (8.2 %)
|
15 (10.6 %)
|
0.783
|
0.999
|
0.999
|
Other pulmonary disorder
|
14 (5.6 %)
|
7 (7.1 %)
|
13 (9.2 %)
|
0.435
|
0.999
|
0.999
|
Symptoms at IPF diagnosis, N (%)b
|
Dyspnea/shortness of breath
|
209 (83.6 %)
|
88 (89.8 %)
|
132 (93.0 %)
|
0.030*
|
0.999
|
0.668
|
Cough
|
175 (70.0 %)
|
71 (72.4 %)
|
110 (77.5 %)
|
0.428
|
0.999
|
0.999
|
Fatigue or malaise
|
107 (42.8 %)
|
47 (48.0 %)
|
78 (54.9 %)
|
0.145
|
0.999
|
0.999
|
Rapid, shallow breathing
|
25 (10.0 %)
|
11 (11.2 %)
|
14 (9.9 %)
|
0.999
|
0.999
|
0.999
|
Gradual, unintended weight loss
|
17 (6.8 %)
|
9 (9.2 %)
|
24 (16.9 %)
|
0.035*
|
0.317
|
0.999
|
Clubbing
|
14 (5.6 %)
|
11 (11.2 %)
|
17 (12.0 %)
|
0.309
|
0.999
|
0.321
|
Other
|
1 (0.4 %)
|
0 (0.0 %)
|
2 (1.4 %)
|
-
|
-
|
-
|
GAP index, mean (SD)c
|
3.3 (1.5)
|
3.5 (1.5)
|
3.7 (1.4)
|
0.149
|
0.999
|
0.774
|
Lung-function measures at IPF diagnosis, mean [median] (SD)
|
FVC (liters)
|
2.6 (1.1)
|
2.4 (0.9)
|
2.4 (1.0)
|
0.821
|
0.999
|
0.796
|
FVC%
|
61.7 %(26.1 %)
|
58.5 % (24.0 %)
|
59.5 % (27.6 %)
|
0.999
|
0.999
|
0.999
|
FEV1 (liters)
|
2.0 (0.9)
|
1.8 (0.7)
|
1.7 (0.6)
|
0.021*
|
0.901
|
0.395
|
FEV1/FVC
|
79.6 % (12.6 %)
|
79.9 % (11.8 %)
|
80.7 % (12.5 %)
|
0.999
|
0.999
|
0.999
|
DLCO percent predicted
|
53.4 % (14.4 %)
|
51.2 % (16.1 %)
|
47.7 % (16.5 %)
|
0.033*
|
0.583
|
0.962
|